Exosens: forecasts exceeded in 2024
(CercleFinance.com) - For 2024, Exosens forecasts total sales growth of over 34% to E390m-E395m, as well as adjusted EBITDA of E116m-E118m, meaning a margin of around 30%, thus exceeding its outlook announced on the IPO.
For 2025, the critical amplification, detection and imaging technologies company anticipates sales growth in the upper 15%-20% range, and adjusted EBITDA growth in the lower 20%-25% range.
The overall increase in market demand improves its outlook, implying an average annual growth rate in adjusted EBITDA in the upper 15%-20% range over 2024-2026, and a cash conversion ratio between 75% and 80% over the same period.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
For 2025, the critical amplification, detection and imaging technologies company anticipates sales growth in the upper 15%-20% range, and adjusted EBITDA growth in the lower 20%-25% range.
The overall increase in market demand improves its outlook, implying an average annual growth rate in adjusted EBITDA in the upper 15%-20% range over 2024-2026, and a cash conversion ratio between 75% and 80% over the same period.
Copyright (c) 2025 CercleFinance.com. All rights reserved.